United States Patent 8,895,616: Claim Scope, Gocovri Relevance, and Amantadine Patent Landscape

U.S. Patent No. 8,895,616 is a method-of-treatment patent directed to once-daily administration of extended-release amantadine for Parkinson's disease. Its core limitation is pharmacokinetic: at least 50% of the administered amantadine must be extended release, and the resulting post-dose plasma concentration slope between two and four hours must be less than 30% of the slope produced by an equivalent immediate-release dose between zero and two hours. The patent is highly relevant to extended-release amantadine products, particularly Adamas Pharmaceuticals' Gocovri, now marketed by Supernus Pharmaceuticals.

The broadest claim covers a once-daily 200 mg to 500 mg amantadine regimen. The dependent claims add narrower dose ranges, extended-release percentages, dyskinesia treatment, levodopa coadministration, delayed Tmax, osmotic delivery, maintained bioavailability, and immediate therapeutic effect.

What does U.S. Patent 8,895,616 protect?

The patent protects a dosing method rather than a particular chemical form of amantadine or a single capsule design. Claim 1 requires all of the following:

Claim element	Scope
Patient	Human subject with Parkinson's disease
Route	Oral administration
Frequency	Once daily
Amantadine amount	200 mg to 500 mg
Active ingredient	Amantadine or a pharmaceutically acceptable salt
Formulation	At least 50% of the drug in extended-release form
Pharmacokinetic result	dC/dT between 2 and 4 hours is less than 30% of the immediate-release comparator slope between 0 and 2 hours
Composition	At least one excipient

The claim is therefore a hybrid formulation-and-method claim. It does not merely require an extended-release tablet or capsule. The administered product must produce a specified pharmacokinetic profile in a single-dose human pharmacokinetic study.

That limitation narrows the claim in one respect and strengthens its product relevance in another. A generic manufacturer could avoid infringement by using extended-release amantadine that does not meet the claimed pharmacokinetic threshold, but proving non-infringement would likely require human pharmacokinetic data rather than only dissolution testing or formulation descriptions.

How do the dependent claims narrow the patent?

Claims 2 through 14 create multiple fallback positions.

Claim	Additional limitation	Commercial significance
2	300 mg to 500 mg	Excludes doses below 300 mg
3	At least 75% extended release	Captures predominantly extended-release products
4	Immediate-release amantadine also included	Covers mixed-release dosage forms
5	At least 90% extended release	Narrower formulation profile
6	Therapeutically effective for Parkinson's disease	Adds a treatment-effect limitation
7	Patient suffers from dyskinesia	Targets a Parkinson's subpopulation
8	Reduces dyskinesia frequency or severity	Adds a clinical outcome
9	Dyskinesia is levodopa-induced	Directly targets levodopa-induced dyskinesia
10	Levodopa/carbidopa is also administered	Protects combination treatment
11	Tmax shifts by 2 to 16 hours versus immediate release	Adds a delayed-absorption requirement
12	Osmotic device provides extended release	Covers osmotic delivery technology
13	Bioavailability is maintained	Limits the pharmacokinetic effect on exposure
14	Therapeutically effective dose from treatment onset	Addresses initial dosing rather than titration

The most commercially important dependent claims are claims 7 through 10. They tie the patent to the treatment of dyskinesia, especially levodopa-induced dyskinesia, which is the principal therapeutic use of Gocovri.

What formulation and pharmacokinetic features are protected?

The patent's principal technical concept is a slow early exposure profile after once-daily dosing. The dC/dT limitation compares two different portions of two human pharmacokinetic profiles:

The extended-release product is evaluated from two to four hours after administration.
The immediate-release comparator is evaluated from zero to two hours after administration.
The extended-release slope must be less than 30% of the immediate-release slope.

This is not a conventional dissolution limitation. It is a functional pharmacokinetic limitation. The claim does not specify a particular dissolution apparatus, release medium, polymer, coating, tablet geometry, capsule structure, or manufacturing process.

The claim also requires a once-daily dose containing 200 mg to 500 mg of amantadine. That range is materially broader than the 274 mg maintenance dose used for Gocovri, because a 274 mg daily dose falls within the claim's 200 mg to 500 mg range. The range also encompasses potential 300 mg, 400 mg, and 500 mg products.

Claim 11 adds a Tmax delay of two to 16 hours compared with immediate-release amantadine. This limitation is important because it links the claimed concentration profile to delayed absorption rather than merely lower exposure. Claim 13 prevents the claim from being read only on products that reduce bioavailability. The intended covered product maintains overall amantadine exposure while flattening the early concentration rise.

Does the patent cover Gocovri?

Gocovri is an extended-release amantadine product approved for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic therapy. The FDA-approved regimen is once daily at bedtime, generally titrated to 274 mg daily. The product is supplied as extended-release capsules containing amantadine hydrochloride [FDA, 2023].

The approved Gocovri regimen aligns closely with the principal limitations of claim 1:

Gocovri characteristic	Claim 1 relationship
Amantadine hydrochloride	Falls within amantadine pharmaceutically acceptable salts
Once-daily administration	Expressly required
Parkinson's disease	Expressly required
Dyskinesia indication	Covered by claims 7 through 9
274 mg maintenance dose	Falls within 200 mg to 500 mg
Extended-release capsule	Satisfies the formulation direction if the pharmacokinetic test is met
Levodopa-based treatment	Relevant to claim 10
Delayed exposure	Relevant to the dC/dT and Tmax limitations

The product's exact infringement position depends on the pharmacokinetic data and the construction of the claim's comparator methodology. A product can be compositionally similar to Gocovri without infringing if it does not produce the claimed dC/dT relationship. Conversely, a product with a different capsule, polymer, or manufacturing process could still fall within the method claims if its administered dose produces the claimed pharmacokinetic profile.

What is the FDA and Orange Book status of U.S. Patent 8,895,616?

Gocovri was approved under NDA 208944. The FDA Orange Book identifies patents associated with the product's approved indications and labeling. U.S. Patent 8,895,616 has been associated with the Gocovri patent estate and is relevant to the product's once-daily extended-release amantadine regimen [FDA, 2024a].

The patent is a method-of-use patent, not a patent limited to the chemical identity of amantadine. Its Orange Book value therefore depends on the relationship between the approved labeling and the claimed treatment method. A generic applicant may pursue a Paragraph IV certification against listed patents or attempt to omit the patented indication through a section viii statement, depending on the patent listing and the proposed label under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The original patent term is tied to the earliest effective nonprovisional filing date in the patent family. Public patent records identify a May 25, 2005 priority date for the relevant family. The nominal 20-year term therefore places the base expiration in 2025, subject to the patent's actual effective filing date, patent-term adjustment, terminal disclaimers, and any statutory extension recorded by the USPTO [USPTO, 2014; USPTO, 2024]. Later continuation patents in the Gocovri family can extend protection beyond the expiration of this patent even if the claims overlap commercially.

When does U.S. Patent 8,895,616 lose exclusivity?

The patent's base term reaches its 20-year endpoint in 2025 based on the publicly identified May 25, 2005 family priority date. The operative expiration date must be taken from the USPTO patent record and the Orange Book listing because patent-term adjustment can change the date.

Expiration of U.S. Patent 8,895,616 does not eliminate all Gocovri-related barriers. The relevant landscape includes later patents covering:

Extended-release amantadine formulations
Capsule or multiparticulate structures
Specific release profiles
Treatment of dyskinesia
Parkinson's disease dosing regimens
Combination treatment with levodopa
Manufacturing and formulation processes

A generic applicant therefore must evaluate the full listed patent estate, not only U.S. Patent 8,895,616. FDA drug exclusivity is separate from patent protection. Gocovri's regulatory exclusivity periods run independently from the patent term and do not automatically extend this patent.

What Paragraph IV and generic-entry risks exist?

A Paragraph IV challenge could attack the patent on several grounds:

Non-infringement

A generic sponsor could argue that its product does not satisfy one or more mandatory limitations, including:

The 200 mg to 500 mg dose range
Once-daily administration
At least 50% extended-release amantadine
The dC/dT threshold
The claimed Parkinson's disease or dyskinesia indication
The Tmax shift in claim 11
The osmotic-device limitation in claim 12

The dC/dT limitation creates a potentially important non-infringement path. A generic product may use extended release but produce a higher early plasma concentration slope than the claimed threshold.

Invalidity

Potential invalidity theories include:

Anticipation by earlier extended-release amantadine disclosures
Obviousness based on immediate-release amantadine, known sustained-release systems, and Parkinson's treatment literature
Lack of written description for the full 200 mg to 500 mg range or broad pharmacokinetic result
Lack of enablement for every formulation and dose that could satisfy the functional limitation
Indefiniteness of the comparative dC/dT measurement, particularly the study design and comparator requirements

The patent's human-pharmacokinetic limitation can create both enforcement value and validity exposure. It distinguishes the claim from a simple sustained-release formulation claim, but the claim must provide a sufficiently reproducible test for determining whether a product meets the 30% threshold.

Label-based avoidance

A generic applicant could seek approval with a label that omits dyskinesia or other protected uses. That strategy is more difficult when the dosage regimen itself is central to the patent and when the FDA-approved product has a narrow clinical use. A section viii strategy would depend on the exact Orange Book listing and the generic label.

Which companies are relevant to the amantadine extended-release landscape?

The principal commercial parties include:

Company	Product or role	Patent relevance
Supernus Pharmaceuticals	Gocovri	Commercial holder of the principal extended-release amantadine product
Adamas Pharmaceuticals	Original Gocovri developer	Originator and historical patent owner
Osmotica Pharmaceutical	Osmolex ER	Competing extended-release amantadine product
Generic drug applicants	Potential ANDA sponsors	May challenge listed patents or design around claim limitations
FDA	NDA and Orange Book regulator	Determines approval, labeling, and patent-listing framework
USPTO	Patent-granting authority	Maintains patent term, prosecution, and continuation records

Osmolex ER is a relevant comparator because it is an extended-release amantadine product, but its approved indications, dosage form, release technology, and patent estate differ from Gocovri. Similarity at the active-ingredient level does not establish infringement of U.S. Patent 8,895,616.

How does U.S. Patent 8,895,616 compare with competing amantadine patents?

Issue	U.S. 8,895,616	Later or competing patents
Claim type	Method of treatment	May claim composition, dosage form, process, or method
Core feature	Once-daily dose and plasma concentration slope	Often more product-specific
Active ingredient	Amantadine or pharmaceutically acceptable salts	Usually amantadine-based
Dose	200 mg to 500 mg	May use narrower commercial doses
Disease	Parkinson's disease	May include dyskinesia or broader neurologic uses
Formulation	At least 50% extended release	May claim beads, coatings, polymers, or release stages
Pharmacokinetics	Express dC/dT threshold; optional Tmax shift	May use dissolution or exposure parameters
Generic vulnerability	Human-study and claim-construction issues	Product-specific claims may be easier to test but harder to design around

The patent is broader than a claim limited to a specific capsule or polymer, but it is narrower than a claim covering every extended-release amantadine product. Its enforceability depends on whether the accused product satisfies the specified clinical pharmacokinetic profile.

How strong is the patent estate for Gocovri?

U.S. Patent 8,895,616 has meaningful commercial relevance because the claimed dose and indication map closely to the Gocovri label. Its strongest features are:

The 200 mg to 500 mg range covers the commercial 274 mg daily dose.
The claim targets once-daily treatment, a defining commercial attribute.
Claims 7 through 10 address dyskinesia and levodopa-associated treatment.
The pharmacokinetic limitation is directed to the intended product behavior rather than a nominal formulation label.

Its principal weaknesses are:

The base patent term reaches its endpoint in 2025 based on the relevant family date.
The claim depends on a comparative human pharmacokinetic test that may generate factual disputes.
The functional limitation may invite written-description, enablement, and indefiniteness challenges.
A generic sponsor may pursue a formulation with a different early exposure profile.
Later patents, not this patent alone, determine the practical timing of generic entry.

What manufacturing and IP barriers remain after expiration?

The patent does not claim every manufacturing method for extended-release amantadine. A competitor may design around it by using:

A different release mechanism
A different dose outside the claimed range
A different dosing frequency
A product that fails the claimed dC/dT relationship
A label that omits protected indications, where legally and regulatorily available
A formulation with different bioavailability or Tmax characteristics

The practical barriers remain substantial when the commercial objective is to replicate Gocovri's label, dosing schedule, and dyskinesia indication. Manufacturing equivalence, bioequivalence, multiparticulate release behavior, and FDA labeling requirements may constrain design-around options even when the patent claim can be avoided.

What litigation and settlement issues affect generic entry?

A Paragraph IV notice concerning a listed Gocovri patent can trigger a 45-day period for the patent holder to file suit and can create a 30-month stay of ANDA approval under the Hatch-Waxman framework, subject to statutory exceptions and court rulings. The relevant litigation analysis must cover each listed patent and each asserted claim.

For U.S. Patent 8,895,616, the central litigation disputes would likely involve:

Whether the generic label induces practice of the claimed Parkinson's or dyskinesia method
Whether the proposed dose is within 200 mg to 500 mg
Whether the product satisfies the extended-release percentage
Whether the dC/dT comparison is met
Whether the patent is invalid over earlier sustained-release amantadine disclosures
Whether later-filed continuation patents remain enforceable after this patent expires

A settlement could provide an agreed generic-entry date, a license, or a covenant concerning specific claims. Public FDA and court records should be used to distinguish a filed Paragraph IV notice, a patent suit, a consent judgment, and a commercial settlement. Those events have different consequences for approval timing and launch risk.

What is the likely generic launch scenario?

The most plausible launch paths are:

Scenario	Result
No Paragraph IV challenge	Generic entry waits for patent and exclusivity barriers to clear
Paragraph IV challenge with no timely suit	FDA approval may proceed after the statutory framework is satisfied
Patent litigation with 30-month stay	Approval timing depends on litigation and court orders
Successful non-infringement or invalidity case	Earlier launch becomes possible
Design-around product	Launch depends on bioequivalence, labeling, and remaining patents
Expiration of 8,895,616 but later patents remain	Generic entry may still be blocked or commercially constrained
Skinny-label approval	Entry may occur for unprotected indications while omitting patented uses

Revenue exposure is concentrated in the period before the expiration of the full Gocovri patent estate. The expiration of one method patent can reduce legal protection without producing immediate generic competition if other Orange Book-listed patents remain in force.

Key Takeaways

U.S. Patent 8,895,616 claims once-daily oral extended-release amantadine treatment for Parkinson's disease.
Claim 1 covers 200 mg to 500 mg of amantadine, with at least 50% in extended-release form.
The defining limitation is a human pharmacokinetic dC/dT relationship, not merely a sustained-release formulation.
The 274 mg Gocovri maintenance dose falls within the claim's dose range.
Claims 7 through 10 directly target dyskinesia, levodopa-induced dyskinesia, and levodopa/carbidopa coadministration.
The patent's base term reaches its nominal endpoint in 2025 based on the relevant May 25, 2005 family date, subject to the recorded effective expiration date.
Expiration of this patent does not necessarily permit immediate Gocovri generic entry because later patents, FDA exclusivity, litigation stays, and label restrictions may remain.
The primary generic defenses are non-infringement based on pharmacokinetics, label-based avoidance, formulation design-around, anticipation, obviousness, enablement, written description, and indefiniteness.

FAQs About U.S. Patent 8,895,616

Does U.S. Patent 8,895,616 claim amantadine itself?

No. It claims a method of orally administering specified once-daily extended-release amantadine doses to a human with Parkinson's disease.

Does the patent cover all extended-release amantadine products?

No. The product must satisfy the dose, dosing-frequency, extended-release, disease, and pharmacokinetic limitations. Products outside those parameters may avoid the claims.

Is Gocovri the main commercial product associated with this patent?

Yes. Gocovri's once-daily extended-release amantadine regimen and dyskinesia indication closely correspond to the patent's principal and dependent claims.

Can a generic manufacturer avoid the patent by changing the capsule design?

Potentially, but capsule redesign alone is not determinative. A product with a different physical design could still infringe if its administered dose produces the claimed pharmacokinetic profile.

Does patent expiration automatically authorize generic Gocovri approval?

No. FDA approval also depends on applicable regulatory exclusivity, other Orange Book-listed patents, Paragraph IV litigation, bioequivalence, and the proposed generic label.

References

Adamas Pharmaceuticals, Inc. (2014). U.S. Patent No. 8,895,616: Methods and compositions for treating Parkinson's disease. United States Patent and Trademark Office.
Food and Drug Administration. (2023). Gocovri (amantadine) extended-release capsules: Prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024b). Drugs@FDA: Gocovri, NDA 208944. U.S. Department of Health and Human Services.
United States Patent and Trademark Office. (2024). Patent Center: U.S. Patent No. 8,895,616 and related patent-family records. U.S. Department of Commerce.
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2588296	⤷ Start Trial
European Patent Office	1845968	⤷ Start Trial
European Patent Office	2623099	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2006058236	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,895,616

Summary for Patent: 8,895,616